Capricor Therapeutics (NASDAQ:CAPR) received a $9.00 target price from HC Wainwright in a report released on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock.

Several other research firms also recently issued reports on CAPR. ValuEngine raised shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Zacks Investment Research raised shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th. TheStreet raised shares of Capricor Therapeutics from a “d” rating to a “c-” rating in a research note on Tuesday, July 10th. Finally, Maxim Group assumed coverage on shares of Capricor Therapeutics in a research note on Wednesday, May 16th. They set a “buy” rating and a $7.00 price target on the stock. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Capricor Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $5.83.

Capricor Therapeutics traded down $0.10, hitting $1.10, during midday trading on Friday, MarketBeat reports. 277,164 shares of the stock were exchanged, compared to its average volume of 346,417. Capricor Therapeutics has a 1 year low of $0.96 and a 1 year high of $4.25. The company has a market capitalization of $34.93 million, a price-to-earnings ratio of -2.50 and a beta of -3.22.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). Capricor Therapeutics had a negative return on equity of 238.25% and a net margin of 111.24%. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.41 million. sell-side analysts predict that Capricor Therapeutics will post -0.48 earnings per share for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured Story: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.